



Curriculum Vitae

Personal information **Andrea Logreco**

Work experience

1. Employer: Marketing Authorization Office _ Italian Medicines Agency (AIFA) (Italy)
 - Start date: 102019
 - End date:
 - Position: Pharmacist _PK Assessor
 - Activities: _Assessment of the pharmacokinetics study of full and abbreviated applications; _PK assessor of new MR/DC applications where IT acts as RMS; _PK assessor of new MR/DC applications where IT acts as CMS; _PK assessor of new National applications; _Language Reviewer (English _Italian) of Medicinal Products Information;
 - Country: Italy
2. Employer: Post Marketing Surveillance Department _ Italian Medicines Agency AIFA _ Italian Medicines Agency (AIFA) (Italy)
 - Start date: 032019
 - End date: 092019
 - Position: Pharmacist _ PhV Assessor
 - Activities: Evaluation of national active pharmacovigilance studies
 - Country: Italy
3. Employer: Department of Hospital Pharmacy, ASL Abruzzo 02, Chieti
 - Start date: 032018
 - End date: 022019
 - Position: Hospital Pharmacist
 - Activities: Pharmacist in the oncology department
 - Country: Italy
4. Employer: Department of Hospital Pharmacy, Spirito Santo Hospital, Pescara
 - Start date: 092015
 - End date: 022018
 - Position: Hospital Pharmacist
 - Activities: Pharmacist
 - Country: Italy

Education and training

1. Subject: University G. d'Annunzio of Chieti _ Pescara
 - Start date: 102009
 - End date: 032015
 - Qualification: Degree in pharmacy
 - Organisation:
 - Country: Italy
2. Subject: Univeristy of Camerino
 - Start date: 092015
 - End date: 052019
 - Qualification: Postgraduate in Hospital Pharmacy
 - Organisation:
 - Country: Italy
3. Subject: University Cattolica del Sacro Cuore _ Rome
 - Start date: 032021
 - End date: 022022
 - Qualification: II level University Master Degree in Biostatistics and Epidamiology
 - Organisation:
 - Country: Italy

Additional information

Publications

_Persistence and adherence to androgen deprivation therapy in men with prostate cancer: an administrative database study. *Minerva Urologica e Nefrologica* 2020 October;72(5):615_21 _ Cancer drugs for solid tumors approved by the EMA since 2014: an overview of pivotal clinical trials. *European Journal of Clinical Pharmacology* volume 76, pages843–850 (2020) _L'uso della vancomicina: proposta di una metodologia per il calcolo della giusta dose". *GIFaC* 2019; 33(2): 58_67. _Time factor in antiretroviral adherence_ analysis of adherence to singletablet regimens versus multiple _tablet regimens over a 5_ year period. Springer International Publishing AG, part of Springer Nature 2018.doi.org/10.100/s40267_018_0491_5. _Using a treatment diary to improve the medication adherence in patients with Chronic Myeloid Leukemia. *Oncol Pharm Practice* 0(0) 1–7. _Studio osservazionale retrospettivo di confronto tra lo studio sperimentale LUNG 7 e la real practice dei farmaci Afatinibe Gefitinib relativo a pazienti affetti da carcinoma polmonare non a piccole cellule (NSCLC) con mutazione EGFR positiva naive al trattamento con inibitori delle Tirosin_ chinasi (TKI)" *GIFaC* 2017; 31(3): 98_103. _Medication Adherence, Persistence and Cost in Multiple Sclerosis Patients_ Oral vs Parenteral Treatment". *Int J Pharma Sci Res* 2016, 3: 117.

Projects

Memberships

Other Relevant Information